A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study of vismodegib in patients with IPF. Eligible patients will be randomized in a 2:1 ratio to one of two treatment arms: vismodegib or placebo. The duration of treatment will be 52 weeks. Study drug will be administered daily by the oral route. An 8-week safety follow-up period is included for all patients who receive at least one dose of study drug.
Epistemonikos ID: 11c376bd0daae27d2dbafb7a43ccaf9eab0ad281
First added on: May 11, 2024